Prospects for passive immunity to prevent HIV infection.

about

The end of HIV: Still a very long way to go, but progress continues.Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART Engineering multi-specific antibodies against HIV-1

P2860

Q46068428-AD6E1A8C-75FA-49DA-B25F-54067A06934D Q58585537-D8B3F086-377B-40AE-9B89-E403F1F7881B Q58696428-8AD9720F-E9D7-4778-B605-1095F37833F3

P2860

Prospects for passive immunity to prevent HIV infection.

Item

http://www.wikidata.org/entity/Q46621371

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prospects for passive immunity to prevent HIV infection.

@en

Prospects for passive immunity to prevent HIV infection.

@nl

type

Item

label

Prospects for passive immunity to prevent HIV infection.

@en

Prospects for passive immunity to prevent HIV infection.

@nl

prefLabel

Prospects for passive immunity to prevent HIV infection.

@en

Prospects for passive immunity to prevent HIV infection.

@nl

P1476

Prospects for passive immunity to prevent HIV infection.

@en

P2093

Nonhlanhla N Mkhize

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

History of passive antibody administration for prevention and treatment of infectious diseases.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

P304

e1002436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1371/JOURNAL.PMED.1002436

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lynn Morris

P5008

ScienceSource

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29136030

http://www.w3.org/2001/XMLSchema#string

P921

human immunodeficiency virus infectious disease

Retroviridae infectious disease

globulins

blood proteins

biomedical investigative technique

P932

5685477

http://www.w3.org/2001/XMLSchema#string

Prospects for passive immunity to prevent HIV infection.

about

P2860

P2860

Prospects for passive immunity to prevent HIV infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932